Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X about a paper he co-authored with colleagues published in Leukemia:

“Updated results of our frontline trial of FLAG-IDA+VEN, showing CRc in 95% of newly diagnosed AML. Responses were seen across all ELN22 risk groups, with 90% MRD neg. In RR AML, 79% first salvage and TP53wt attained CRc.”

“Long-term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia”

Authors: Courtney DiNardo, Wei-Ying Jen, Koichi Takahashi, Marina Konopleva, Hagop Kantarjian et al.

Hagop Kantarjian: Updated results of our frontline trial of FLAG-IDA+VEN

More posts featuring Hagop Kantarjian.